Atreca Presents Novel Immunotherapy Approach at Precision Medicine World Conference (PMWC 2023); Complete Remission of Metastatic Melanoma Highlighted

On January 27, 2023, Tito Serafini, PhD, Chief Strategy Officer at Atreca, presented the company in an Emerging Therapeutics Showcase at the Precision Medicine World Conference (PMWC 2023) (January 25-27). The title of his presentation was “Delivering the Potential of Immunotherapy.” Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its unique discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as the company’s lead product candidate ATRC-101, its pipeline of lead-stage oncology programs, and MAM01/ATRC-501, a clinical candidate licensed to the Bill & Melinda Gates Medical Research Institute for the prevention of malaria.

Login Or Register To Read Full Story